Insights on Clinical Trials
-
Pros And Cons Of Basing Clinical Trials In Today’s European Landscape
1/31/2024
Explore the essential considerations for sponsors and CROs as they navigate the advantages and challenges of clinical trial locations, particularly in the United States and Europe.
-
Global Strides In HIV Research: Mapping The Clinical Trial Terrain
1/31/2024
Uncover how ongoing research exploring innovative pathways is serving as a beacon of hope for HIV, promising not only an eventual cure but also an enhanced quality of life for those affected.
-
An Exploration Of ICIs In Cancer Therapy
1/31/2024
This collection of frequently asked questions highlights the remarkable efficacy of immune checkpoint inhibitors (ICIs) and the projected growth of the global ICI market.
-
FDA Draft Guidance On “Rare Diseases: Considerations For The Development Of Drugs And Biological Products”
1/26/2024
Accenture Applied Life Science Solutions' Raj Bandaru, Ph.D. breaks down, summarizes, and shares detailed insight on the recent FDA Draft Guidance that addresses “Rare Diseases: Considerations for the Development of Drugs and Biological Products.”
-
Cell And Gene: Regulating Rare Disease Study Design
1/22/2024
More than 300 million people worldwide live with a rare disease, and regulatory requirements don't change for demonstrating their safety and efficacy. The FDA has acknowledged the need for additional flexibility in applying these standards to rare diseases, as well as a willingness to rely on less certainty when appropriate.
-
Kriya Therapeutics' Announcements At JPM
1/22/2024
I caught up with Kriya Therapeutics' Dr. Shankar Ramaswamy to discuss the company's announcements at JPM 2024.
-
Don’t Sign Yet: How To Detect And Avoid Hidden CRO Contract Costs
1/22/2024
Navigating the complex landscape of clinical trials can be challenging. Utilize this reliable CRO Checklist to empower teams to stay ahead and safeguard every trial's budget effectively.
-
Let’s Get SMART On Adverse Events
1/17/2024
One of the biggest risks for medical products and companies is the failure to report adverse events. But what leads to underreporting? Here are five core reasons behind most adverse event underreporting.
-
Everyone’s Talking About: Our Most Read Blogs Of 2023
1/17/2024
Discover the latest insights and trends shaping the landscape of clinical trials, like SMART on FHIR, patient-centered trials, eSource, and eConsent, with OpenClinica's most popular blogs of 2023.
-
The Future Of mRNA For Cancer Treatment
1/9/2024
As additional mRNA-based cancer immunotherapies vaccines enter clinical development, operational and supply chain challenges must be addressed to reduce turnaround times and COGS.